Study S000341

The Effect of Glucagon-like Peptide 1 (GLP-1) Receptor Agonist on Cerebral Blood Flow Velocity in Non-Stroke Volunteers (EGRABINS1)

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT02838589
Acronym: EGRABINS1
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 30
Start: 2016-08
Primary completion: 2017-02
Lead sponsor: Christina Kruuse
Conditions: Stroke
Interventions: DRUG:Byetta; DRUG:Isotonic saline
Results posted: FALSE
Individual participant data sharing: NO
Secondary identifiers: EUDRACT_NUMBER:2016-001221-14; NIH:2016

Registered primary outcomes

Changes in the mean flow velocity in the middle cerebral arteries and in cortical oxigination . [Up till 3 hours]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0014007	A single dose of exenatide had no effect on blood flow velocity in the middle cerebral artery in elderly healthy volunteers: Randomized, placebo-controlled, double-blind clinical trial. Ölmestig J, Frontiers in aging neuroscience	2022	Randomized trial	PMID 36636739 DOI	cites ClinicalTrials.gov:NCT02838589; registry reference DERIVED:36636739